BELTRONICS VECTOR FX PRO TRIAL
BELTRONICS VECTOR FX PRO PLUS

I first did a run with 3000lbs as the weight (that weight was setup for when I had a passenger with me the other day). I think those two that are the only ones that really matter.

BELTRONICS VECTOR FX PRO PLUS

What was programmed into the Vector FX 2:Ĭar Weight: 2850 lbs (Thats 2617lbs stock, plus me and the tool shed in the trunk)ĬDA: 8.00 Left this one at 8's for now, still need to figure out an accurate CDA I did a run today after installing half of the thermoblock kit. REDWOOD CITY - Adverum Biotechnologies, Inc.Alright thought I would fill this thread in with some numbers (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced new data will be presented during the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting being held May 16-20, 2023, in Los Angeles, California.Īt ASGCT 2023, Adverum will unveil new nonclinical data on the development of an IVT gene therapy for the treatment of geographic atrophy through the overexpression of Complement Factor I (CFI). CFI is a rate-limiting enzyme in the complement cascade, naturally inhibiting the activity of proteins involved in complement overactivation. Continuous overexpression of CFI in ocular tissue inhibits the complement cascade in the eye and has the potential to halt lesion growth and preserve vision in patients with geographic atrophy secondary to age-related macular degeneration. Adverum designed and evaluated an optimized human CFI cassette using its two proprietary capsids 7m8 and LSV1 enabling IVT delivery.

BELTRONICS VECTOR FX PRO TRIAL

Both capsids demonstrated potent CFI levels in nonhuman primates (NHP), suggesting potential for continuous therapeutic levels of CFI in humans with a potential one-and-done outpatient IVT injection.Īdverum will also deliver data presentations on Ixo-vec (ixoberogene soroparvovec, formerly ADVM-022) currently being evaluated in the Phase 2 LUNA trial in wet age-related macular degeneration (wet AMD).

The first of two oral presentations will feature nonclinical data in NHP that support staggered bilateral administration of Ixo-vec in the treatment of wet AMD. Bilateral treatment is an area of unmet need where incidence of neovascularization (nAMD) in the second eye is up to 42% in the first two to three years following diagnosis in the primary eye. The second oral presentation will focus on identification of dose-dependent inflammation pathways involved in innate and adaptive immune response that are commonly observed in gene therapy.

Poster Presentation: Development of an Intravitreal (IVT) Gene Therapy for Geographic Atrophy (GA) by Overexpressing Complement Factor I (CFI) to Inhibit the Complement Cascadeĭate & Time: Thursday, May 18, 2023, 12:00 pm PDT Poster Presentation: Engineered Melanopsin Mutants for Optogenetic Vision Restoration Poster Presentation: CMC Strategies for AAV Gene Therapies for Highly Prevalent Diseasesĭate & Time: Wednesday, May 17, 2023, 12:00 pm PDT Session: Understanding and Modeling Immune Responses to Gene Therapy and Vaccinesĭate & Time: Thursday, May 18, 2023, 2:00 pm - 2:15 pm PDT Oral Presentation: Identification of Dose-Dependent Immune Landscape Signatures Following Administration of Ixo-vec in Non-Human Primates Session: AAV Vectors: Clinical and Non-Human Primate Studiesĭate & Time: Wednesday, May 17, 2023, 4:15 pm - 4:30 pm PDT Oral Presentation Title: Bilateral Ixo-vec NHP Tolerability and Efficacy Following a Staggered Dosing Interval between Eyes - Gene Therapy nAMD Additionally, a poster presentation will focus on Ixo-vec's evaluation of per cell vector genome biodistribution and mRNA expression in NHP.Īdverum will also present new data in an Optogenetics program, as well as Adverum's adeno-associated virus (AAV) advanced chemistry, manufacturing, and controls (CMC) process development platform for highly prevalent ocular diseases.Īdverum abstracts being presented at ASGCT are as follows The data support the 2x10^11 vg/eye (2E11) and 6x10^10 vg/eye (6E10) doses in combination with enhanced corticosteroid prophylactics regimens in the ongoing Phase 2 LUNA trial.

Beltronics vector fx pro